Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

Meredith Jr., Jere E., Sankaranarayanan, Sethu, Guss, Valerie, Lanzetti, Anthony J., Berisha, Flora, Neely, Robert J., Slemmon, J. Randall, Portelius, Erik, Zetterberg, Henrik, Blennow, Kaj, Soares, Holly, Ahlijanian, Michael, Albright, Charles F.·2013·PLoS ONE
DOI 10.1371/journal.pone.0076523

Cited by (209)

Items 101–200 of 209

  1. Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
    Josef Marksteiner, Michaela Defrancesco, Christian Humpel · 2022 · Frontiers in Aging Neuroscience
  2. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers
    Edwin Jabbari, Henrik Zetterberg, Huw R. Morris · 2017 · Journal of Neurology Neurosurgery & Psychiatry
  3. Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer’s Disease and Other Tauopathies
    Jie Yang, Naiting Shen, Jianying Shen, Ying Yang, Hong-Lian Li · 2023 · Molecular Neurobiology
  4. Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures
    Xiaoxia Shen, Huan Li, Beiyu Zhang, Yunan Li, Zheying Zhu · 2025 · Cells
  5. Biomarkers in Alzheimer’s disease
    Manuel H. Janeiro, Carlos G. Ardanaz, Noemí Sola-Sevilla, Jinya Dong, María Cortés-Erice, Maite Solas, Elena Puerta, María Javier Ramírez · 2020 · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
  6. Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
    Jessica Brown, Elena Camporesi, Juan Lantero‐Rodriguez, Maria Olsson, Alice Wang, Blanca Medem, Henrik Zetterberg, Kaj Blennow, Thomas K. Karikari, Mark John Wall et al. · 2023 · Acta Neuropathologica Communications
  7. Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry
    Richard Y.‐C. Huang, Roxana E. Iacob, Sethu Sankaranarayanan, Ling Yang, Michael K. Ahlijanian, Li Tao, Adrienne A. Tymiak, Guodong Chen · 2017 · Journal of the American Society for Mass Spectrometry
  8. The interplay between aging‐associated loss of protein homeostasis and extracellular vesicles in neurodegeneration
    Francesc Xavier Guix · 2019 · Journal of Neuroscience Research
  9. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update
    Erik Portelius, Gunnar Brinkmalm, Josef Pannee, Henrik Zetterberg, Kaj Blennow, Rahil Dahlén, Ann Brinkmalm, Johan Gobom · 2017 · Expert Review of Proteomics
  10. Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures
    Katryna Pampuščenko, Ramunė Morkūnienė, Lukas Krasauskas, Vytautas Smirnovas, Taisuke Tomita, Vilmantė Borutaitė · 2020 · Molecular Neurobiology
  11. Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry
    Eric Vallabh Minikel, Eric W. Kuhn, Alexandra R. Cocco, Sonia M. Vallabh, Christina R. Hartigan, Andrew G. Reidenbach, Jiri Safar, Gregory J. Raymond, Michael D. McCarthy, Rhonda O’Keefe et al. · 2019 · Molecular & Cellular Proteomics
  12. Tau Monoclonal Antibody Generation Based on Humanized Yeast Models
    Joëlle Rosseels, Jeff Van den Brande, Marie Violet, Dirk Jacobs, Pierre Grognet, Juan M. Lopez, Isabelle Huvent, Marina Caldara, Erwin Swinnen, Anthony Papegaey et al. · 2014 · Journal of Biological Chemistry
  13. CSF in Alzheimer's Disease
    Henrik Zetterberg, Ronald Lautner, Tobias Borgh Skillbäck, Christoffer Rosén, Pashtun Shahim, Niklas Mattsson, Kaj Blennow · 2014 · Advances in clinical chemistry
  14. Tau Secretion
    Zhi Ruan, Tsuneya Ikezu · 2019 · Advances in experimental medicine and biology
  15. Neurogranin Levels in Cerebrospinal Fluid
    Henrik Zetterberg, Kaj Blennow · 2015 · JAMA Neurology
  16. Influence of cognitive impairment and race on plasma p‐Tau 217 in two diverse cohorts
    Ashima Nayyar, Mei‐Ling Li, Victor Sotelo, Guibin J Su, Isabelle Hwang, Milota Kaluzová, Mini Jomartin, Michelle Migut, Hilary Grosso Jasutkar, Karlyndsay Sitterley et al. · 2025 · Alzheimer s & Dementia
  17. Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases
    Ann Brinkmalm, Erik Portelius, Gunnar Brinkmalm, Josef Pannee, Rahil Dahlén, Johan Gobom, Kaj Blennow, Henrik Zetterberg · 2018 · Journal of Neurochemistry
  18. Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
    Gallen Triana‐Baltzer, Kristof Van Kolen, Clara Theunis, Setareh Moughadam, Randy Slemmon, Marc H. Mercken, Wendy R. Galpern, Hong Fan Sun, Hartmuth Christian Kolb · 2020 · Journal of Alzheimer s Disease
  19. The Proteoform Landscape of Tau from the Human Brain
    Tian Xu, Taojunfeng Su, Benjamin J. Des Soye, Soumya Kandi, Che‐Fan Huang, John T. Wilkins, Rudolph J. Castellani, Jared O. Kafader, Steven M. Patrie, Robert J. Vassar et al. · 2025 · Journal of Proteome Research
  20. Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
    Mohammad Arastoo, Richard A. Lofthouse, Lewis K. Penny, Charles R. Harrington, Andy Porter, Claude M. Wischik, Soumya Palliyil · 2020 · International Journal of Molecular Sciences
  21. Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases
    Shenqing Zhang, Hui Dong, Jiang Bian, Dan Li, Cong Liu · 2022 · Fundamental Research
  22. The Potential of Pathological Protein Fragmentation in Blood-Based Biomarker Development for Dementia – With Emphasis on Alzheimer’s Disease
    Dilek Inekci, Ditte Svendsen Jonesco, Sophie Kennard, M.A. Karsdal, Kim Henriksen · 2015 · Frontiers in Neurology
  23. AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy
    Antonella Borreca, Valentina Latina, Veronica Corsetti, Silvia Middei, Sonia Piccinin, Francesco Della Valle, Rossana Bussani, Martine Ammassari‐Teule, Robert Nisticò, Pietro Calissano et al. · 2018 · Molecular Neurobiology
  24. Aging and Neuroinflammatory Disorders: New Biomarkers and Therapeutic Targets
    Caterina Maria Gambino, Bruna Lo Sasso, Giulia Bivona, Luisa Agnello, Marcello Ciaccio · 2019 · Current Pharmaceutical Design
  25. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau
    Wendy Luca, Kelly Foster, K. McClure, Michael K. Ahlijanian, Martin R. Jefson · 2024 · The Journal of Prevention of Alzheimer s Disease
  26. Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
    Johan Gobom, Ann Brinkmalm, Gunnar Brinkmalm, Kaj Blennow, Henrik Zetterberg · 2024 · Molecular & Cellular Proteomics
  27. Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer’s disease? An umbrella review
    Hossein Mohammadi, Armin Ariaei, Zahra Ghobadi, Enam Alhagh Charkhat Gorgich, Auob Rustamzadeh · 2024 · IBRO Neuroscience Reports
  28. Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro
    Mar Pérez, Miguel Medina, Félix Hernández, Jesús Ávila · 2018 · BioMolecular Concepts
  29. Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
    Douglas R Galasko · 2015 · Frontiers in Neurology
  30. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease
    Leonie Beyer, Jonas Schnabel, Philipp Maximilian Kazmierczak, Michael Ewers, Sonja Schönecker, Catharina Prix, Johanna Meyer-Wilmes, Marcus Unterrainer, Cihan Catak, Oliver Michael Pogarell et al. · 2019 · NeuroImage Clinical
  31. Tau: a biomarker of Huntington’s disease
    Eva Lepinay, Francesca Cicchetti · 2023 · Molecular Psychiatry
  32. Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: A prospective study
    Jesper Skov Neergaard, Katrine Dragsbæk, Claus Christiansen, M.A. Karsdal, Susanne Brix, Kim Henriksen · 2018 · PLoS ONE
  33. Chronic Neuroinflammation Induced by Lipopolysaccharide Injection into the Third Ventricle Induces Behavioral Changes
    Shufang Na, Xuejiao Duan, Rongyan Wang, Yanjie Fan, Ke Xue, Shuwei Tian, Zheqiong Yang, Ke Li, Jiang Yue · 2021 · Journal of Molecular Neuroscience
  34. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
    Claudia Cicognola, Oskar Hansson, Philip Scheltens, Hlin Kvartsberg, Henrik Zetterberg, Charlotte Elisabeth Teunissen, Kaj Blennow · 2021 · Alzheimer s Research & Therapy
  35. High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples
    Monika Arbaciauskaite, Lei Yu, Yong Ku Cho · 2021 · Antibody Therapeutics
  36. A Quantitative LC-MS/MS Method for Distinguishing the Tau Protein Forms Phosphorylated and Nonphosphorylated at Serine-396
    Anne‐Marie Jacobsen, Nico C. van de Merbel, Dorte Kornerup Ditlevsen, Ketil Tvermosegaard, Frank Schalk, Wietske Lambert, Christoffer Bundgaard, Jan T. Pedersen, Nina Rosenqvist · 2023 · Journal of the American Society for Mass Spectrometry
  37. Preclinical characterization and IND‐enabling safety studies for PNT001, an antibody that recognizes cis‐pT231 tau
    Kelly Foster, Matteo Manca, Kim F. McClure, Pyry P. Koivula, John Q. Trojanowski, Daniel Havas, Sarah E. Chancellor, Lee E. Goldstein, Kurt R. Brunden, Allison Kraus et al. · 2023 · Alzheimer s & Dementia
  38. Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease
    Karl Hansson, Rahil Dahlén, Oskar Hansson, Elin Pernevik, Ross W. Paterson, Jonathan M. Schott, Nadia K. Magdalinou, Henrik Zetterberg, Kaj Blennow, Johan Gobom · 2019 · Clinical mass spectrometry
  39. ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease
    Mitsuru Shinohara, Junko Hirokawa, Akemi Shimodaira, Yoshitaka Tashiro, Kaoru Suzuki, Ghupurjan Gheni, Akio Fukumori, Tomoyasu Matsubara, Maho Morishima, Yuko Saito et al. · 2021 · Journal of Neuropathology & Experimental Neurology
  40. Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease
    Alexander J. Lowe, Filipe Brogueira Rodrigues, Marzena Arridge, Enrico De Vita, Eileanoir B. Johnson, Rachael I. Scahill, Lauren M. Byrne, Rosanna Tortelli, Amanda Heslegrave, Henrik Zetterberg et al. · 2022 · Brain Communications
  41. Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage
    Claudia Cicognola, Tuğçe Munise Şatır, Gunnar Brinkmalm, Irena Matečko‐Burmann, Lotta Agholme, Petra Bergström, Bruno Becker, Henrik Zetterberg, Kaj Blennow, Kina Höglund · 2020 · Journal of Alzheimer s Disease
  42. Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard
    Maotian Zhou, Duc Minh Duong, Erik C. B. Johnson, Jingting Dai, James J. Lah, Allan I. Levey, Nicholas T. Seyfried · 2019 · Journal of Proteome Research
  43. NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression
    Mengel, David, Mok, Tze How, Nihat, Akin, Liu, Wen, Rissman, Robert A., Galasko, Douglas, Zetterberg, Henrik, Mead, Simon, Collinge, John, Walsh, Dominic M. · 2021 · Cells
  44. Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology
    Florent Sauvé, Ricardo Gomez-Martínez, Yvon Mbouamboua, Gaëtan Ternier, Sreekala S. Nampoothiri, Elian Dupré, Lolie Garcia, Marie Couralet, Julie Dewisme, Thibaud Lebouvier et al. · 2026 · Cell Press Blue
  45. Tau Diagnostics and Clinical Studies
    Illana Gozes, Günter U. Höglinger, James P. Quinn, Nigel M. Hooper, Kina Höglund · 2017 · Journal of Molecular Neuroscience
  46. Cerebrospinal fluid in the dementias
    Henrik Zetterberg, Jonathan Daniel Rohrer, Jonathan M. Schott · 2017 · Handbook of clinical neurology
  47. Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer’s disease: implications for biomarker development and therapeutic targeting
    Liara Rizzi, Lea T. Grinberg · 2024 · Acta Neuropathologica Communications
  48. Tauomics and Kinetics in Human Neurons and Biological Fluids
    Henrik Zetterberg · 2018 · Neuron
  49. Platelet TAU is Associated with Changes in Depression and Alzheimer's Disease
    Bettina Sarg, Dhwani S. Korde, Josef Marksteiner, Christian Humpel · 2022 · Frontiers in Bioscience-Landmark
  50. High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease
    Mohammad Arastoo, Lewis K. Penny, Richard A. Lofthouse, Aya Abdallah, Anna Abrahamsson, Pietro Marini, Valeria Melis, Gernot Riedel, Charles R. Harrington, Claude M. Wischik et al. · 2024 · Alzheimer s Research & Therapy
  51. Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias
    Franc Llorens, Anna Villar‐Piqué, Niccolò Candelise, Isidró Ferrer, Inga Zerr · 2019 · IntechOpen eBooks
  52. The Mechanism of Two Benzaldehydes from Aspergillus terreus C23-3 Improve Neuroinflammatory and Neuronal Damage to Delay the Progression of Alzheimer’s Disease
    Minqi Chen, Jinyue Liang, Yi Liu, Yayue Liu, Chunxia Zhou, Pengzhi Hong, Yi Zhang, Zhong‐Ji Qian · 2023 · International Journal of Molecular Sciences
  53. Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies
    Vidya Ramakrishnan, Brendan C. Bender, Jurgen B. Langenhorst, M.O. Magnusson, Michael J. Dolton, J. Shim, Reina N. Fuji, Cecília Monteiro, Edmond Teng, Nastya Kassir et al. · 2024 · The Journal of Prevention of Alzheimer s Disease
  54. Biomarcadores en la enfermedad de Alzheimer
    Manuel H. Janeiro, Carlos G. Ardanaz, Noemí Sola-Sevilla, Jinya Dong, María Cortés-Erice, Maite Solas, Elena Puerta, María Javier Ramírez · 2021 · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
  55. Biomarkers and Their Implications in Alzheimer’s Disease: A Literature Review
    Vincent Marcucci, Jeremy Kleiman · 2021 · Exploratory Research and Hypothesis in Medicine
  56. Investigating the Impact of Sorghum on Tau Protein Phosphorylation and Mitochondrial Dysfunction Modulation in Alzheimer’s Disease: An In Vitro Study
    Nasim Rezaee, Eugene Hone, Hamid Reza Sohrabi, Abdulraheem R. Adisa, Stuart Keith Johnson, Stuart T. Gunzburg, Ralph Nigel Martins, Warnakulasuriya Mary Ann Dipika Binosha Fernando · 2025 · Nutrients
  57. Diagnosing progressive supranuclear palsy: Role of biological and neuroimaging markers
    Benussi A, Borroni B · 2014 · Journal of Alzheimer's Disease & Parkinsonism
  58. Neuroprotective role of Fisetin in Alzheimer's disease: An overview of potential mechanism and clinical findings
    Fardin Nabizadeh · 2024 · Neurology Letters
  59. Emerging drugs for progressive supranuclear palsy
    Nikolaos Giagkou, María Stamelou · 2019 · Expert Opinion on Emerging Drugs
  60. A Sandwich-Type Impedimetric Immunosensor for the Detection of Tau-441 Biomarker
    Khouloud Djebbi, Yang Xiang, Biao Shi, Lyes Douadji, Xiaohan Chen, Jing Liu, Chaker Tlili, Deqiang Wang · 2025 · Bioengineering
  61. Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer’s disease
    Lily Yi Li, Elliya Park, Chunsheng He, Azhar Zahoor Abbasi, Jeffrey Theodore Henderson, Paul E. Fraser, Jack Uetrecht, Andrew Michael Rauth, Xiao Yu Wu · 2024 · Nanotoxicology
  62. hiPSC-neurons recapitulate the subtype-specific cell intrinsic nature of susceptibility to neurodegenerative disease-relevant aggregation
    Ian W. Weidling, Christina N Preiss, Sarah E. Chancellor, Gyan Prakash Srivastava, Lauren Gibilisco, Gen Lin, Melanie S. Brennan, Janice Y. Lee, Lindsay M. Roth, Olga Morozova et al. · 2025 · Acta Neuropathologica Communications
  63. Modifiable risk factors promoting neurodegeneration is associated with two novel brain degradation markers measured in serum
    Jesper Skov Neergaard, Katrine Dragsbæk, Claus Christiansen, Henning Bay Nielsen, Christopher Thomas Workman, Susanne Brix, Kim Henriksen, M.A. Karsdal · 2017 · Neurochemistry International
  64. Homogeneous Femtomolar Detection of P-tau181 via Proximity Extension and CRISPR/Cas Technique
    Huan Liu, Yunyun Liu, Rui Feng, Meiqi Qian, Ying Li, Shaoqin Zhai, Jinghui Song, Xue Qiu · 2025 · Analytical Chemistry
  65. Tau is necessary for Pseudomonas aeruginosa-induced blood-brain barrier dysfunction
    Samantha D Chaney, Allison J. Bauman, Evan-Angelo R. Butlig, Sima Al-Masri, Juliana Montoya Sanchez, Lauren H McAdams, PETER DOAN, Meredith S. Gwin, Troy Stevens, Annie Vogel Ciernia et al. · 2026 · Communications Biology
  66. Metabolomics in the Study of Alzheimer's Disease
    Clara Ibáñez, Alberto Valdés, Virginia García‐Cañas, Carolina Simó · 2014 · Comprehensive analytical chemistry
  67. A liquid chromatography tandem mass spectroscopy approach for quantification of protein methylation stoichiometry
    Grace L. Cooper, Carol J. Huseby, Claire N. Chandler, Jean‐Christophe Cocuron, Ana Paula Alonso, Jeff Kuret · 2018 · Analytical Biochemistry
  68. Molecular profiling in Parkinsonian syndromes: CSF biomarkers
    Federico Paolini Paoletti, Lorenzo Gaetani, Lucilla Parnetti · 2020 · Clinica Chimica Acta
  69. Unbiased high-content screening reveals Aβ- and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer’s patients and high-pathology controls
    Hao Jiang, Thomas J. Esparza, Terrance T. Kummer, David L. Brody · 2021 · PLoS ONE
  70. An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS
    Wade K. Self, Khader Awwad, John P. Savaryn, Michael Schulz · 2022 · PLoS ONE
  71. Genome-Wide Epistasis Study of Cerebrospinal Fluid Hyperphosphorylated Tau in ADNI Cohort
    Dandan Chen, Jin Li, Hongwei Liu, Xiaolong Liu, Chenghao Zhang, Haoran Luo, Yiming Wei, Yang Xi, Hong Liang, Qiushi Zhang · 2023 · Genes
  72. Advancing novel therapies for neurodegeneration through an innovative model for industry–academia collaborations: A decade of the Eisai–UCL experience
    Peter J. Atkinson, Meera Swami, Nicola Ridgway, Malcolm Roberts, Jane Kinghorn, Thomas T. Warner, James M. Staddon, Andrew K. Takle · 2023 · Drug Discovery Today
  73. Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
    Jessica Brown, Elena Camporesi, Juan Lantero‐Rodriguez, Maria Olsson, Alice Wei Ting Wang, Blanca Medem, Henrik Zetterberg, Kaj Blennow, Thomas K. Karikari, Mark John Wall et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  74. Biomarkers in CNS Drug Discovery, Drug Development, and Clinical Implementation
    Valentina Di Caro, Claire Williams, Hilary A. North, Mary E. Hamby · 2025 · Wiley eBooks
  75. Advances in Alzheimer's Disease Biomarkers
    Kuan Li, Yujie Gao, Muxi Liu, Y. Chen · 2024 · Current Alzheimer Research
  76. Tau in Health and Neurodegenerative Diseases
    Dandan Chu, Fei Liu · 2021 · IntechOpen eBooks
  77. CSF tau phosphorylation at T217 and T205 are improved biomarkers of amyloid and tau pathology in Alzheimer disease
    Nicolas R. Barthélemy, Benjamin A. Saef, Yan Li, Brian Andrew Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvadó, Shorena Janelidze, Chihiro Sato et al. · 2022 · Research Square
  78. Method comparison and re-calibration of three top-used immunoassays and one LC-MS/MS assay for four core cerebrospinal fluid biomarkers of Alzheimer’s disease: an explorative study for harmonization
    Yutong Zou, Xiaoli Ma, Chenhui Mao, Shanshan Chu, Tianyi Wang, Wei Jin, Yifei Wang, Songlin Yu, Jing Gao, Ling Qiu · 2025 · Clinica Chimica Acta
  79. Exploring the Protective Effects of Two Alkaloids 1 and 2 from Aspergillus terreus C23–3 on Neuronal Cells by Combining Bioinformatics Prediction and Experimental Verification
    Minqi Chen, Guangming Tang, Yi Zhang, Zhong‐Ji Qian · 2025 · ACS Chemical Neuroscience
  80. NanoGold-enhanced biomimetic sensor for Tau-441 protein detection in serum for Alzheimer's disease diagnosis
    João M.S. Feijão, Daniela S. Oliveira, S. Chiussi, Ana Paula Pêgo, Sofia D. Santos, Felismina T.C. Moreira · 2026 · Bioelectrochemistry
  81. Faculty Opinions recommendation of Tau kinetics in neurons and the human central nervous system.
    Mark John Millan · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  82. Featured Article Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
    Hlin Kvartsberg, Flora Hillegonde Duits, Martin Ingelsson, Niels Andreasen, Kerstin Andersson, Gunnar Brinkmalm, Lars Lannfelt, Lennart Minthon, Oskar Hansson, Ulf Andréasson et al. · 2015
  83. Fluid Biomarkers and Diagnostics
    Henrik Zetterberg, Kaj Blennow · 2016 · Elsevier eBooks
  84. Investigating the mechanisms underlying Alzheimer's disease using a novel organotypic brain slice culture model
    Cara L. Croft · 2016 · Research Portal (King's College London)
  85. The Role of Chromatography in Alzheimer’s Disease Drug Discovery
    Eli Grushka, Nelu Grinberg · 2016 · CRC Press eBooks
  86. Cerebrospinal fluid peptidomics: discovery of endogenous peptides as biomarkers of Alzheimer's disease
    Karl Hansson · 2018 · Gothenburg University Publications Electronic Archive (Gothenburg University)
  87. Investigation of molecular and cellular mechanisms underpinning the neurotoxicity of homocysteine and its metabolites in models of neurodegeneration
    Lisa Strother · 2018 · St Andrews Research Repository (St Andrews Research Repository)
  88. Mechanistic Insight into Tau Fibril Cross-Seeding Barriers: Structural Order and Disorder
    Hilary A. Weismiller · 2019 · Digital Commons - DU (University of Denver)
  89. University College London/University of Gothenburg PhD course “Biomarkers in neurodegenerative diseases” 2019—course organisation
    Ayesha Khatun, Ross W. Paterson, Michael Schöll · 2020 · Alzheimer s Research & Therapy
  90. Tau proteolysis mechanisms and relevance for tauopathies
    James P. Quinn · 2019 · Research Explorer (The University of Manchester)
  91. Characterization of Tau ELISAs for Evaluating Tau Accumulation in the Brains With Alzheimer’s Disease
    Mitsuru Shinohara, Junko Hirokawa, Akemi Shimodaira, Yoshitaka Tashiro, Kaoru Suzuki, Akio Fukumori, Tomoyasu Matsubara, Maho Morishima, Yuko Saito, Shigeo Murayama et al. · 2021 · Research Square
  92. Комплексный метод анализа геометрической точности цилиндров в процессе сборки судовых малоразмерных дизелей
    Яхьяев Насреддин Яхьяевич, Nurulla M. Vagabov · 2009 · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES
  93. Development of Fluid Biomarkers for Alzheimer’s Disease
    Kaj Blennow · 2022 · Cambridge University Press eBooks
  94. Western Agarose Native GeELution (WANGEL) with beta-amyloid and tau: Novel method to elute proteins or peptides using native agarose gels followed by Lumipulse assay
    Dhwani S. Korde, Christian Humpel · 2022 · MethodsX
  95. The Role of Chromatography in Alzheimer’s Disease Drug Discovery
    2016 · Advances in chromatography
  96. Plasma NT1 tau is associated with hypometabolism in Alzheimer’s disease continuum
    Zahra Ghahri Lalaklou, AmirHossein Montazeri Ghahjavarestani, Yasamin Pishkari, Delaram Emami · 2024 · Neurology Letters
  97. Novel Approaches for Feature Extraction and Representation Learning of Alzheimer's Biomarkers
    Aradhna Saini · 2024 · Advances in bioinformatics and biomedical engineering book series
  98. New Research on Biomarkers in Alzheimer’s Continuum
    Immacolata Vecchio, Carmela Colica · 2025 · Reviews on Recent Clinical Trials
  99. Skin Biomarkers of Neurodegenerative Diseases
    Lauren Reilly-Jankowiak, Connor Bargar, Dominic Bunn, Shu G. Chen · 2025 · Springer eBooks
  100. Fluid Markers of Tau Pathology
    Naazneen Khan, Jeffrey L. Dage · 2025 · Springer eBooks